Health officials say it's important to get flu and COVID-19 vaccines ahead of the holidays when respiratory bugs tend to spread ...

Sales of Moderna’s COVID-19 shot exceeded expectations, but the company’s launch of its new RSV vaccine has started slowly.

While Moderna’s Spikevax beat Wall Street estimates in the third quarter, William Blair analyst Myles Minter in a Thursday ...

Moderna (MRNA) got a boost in the third quarter from an earlier US approval of its updated COVID-19 vaccine, underpinning sales growth and helping drive a surprise net income result at the drugmaker.

Ladapo and RFK Jr. would make a great tag-team ushering back in a world of diphtheria, small pox, grippe, horrors and night ...

Days after Pfizer and BioNTech reported surprisingly strong sales of their updated COVID-19 vaccines, Moderna has done the ...

With the possibility of RFK Jr. being involved in health policy in the next administration, vaccination, especially mRNA ...

On Thursday, Moderna Inc (NASDAQ:MRNA) stock is trading higher after the company reported better-than-expected third-quarter ...

Moderna shares jumped after the biotechnology company reported higher-than-expected sales of its Covid-19 vaccine and backed ...

The top-line beat was led by its higher than anticipated sales of Covid-19 vaccine, while its recently approved respiratory syncytial virus vaccine raked in just $10 ...

Cambridge, Mass.-based Moderna (MRNA) had a net profit of $13 million, or 3 cents a share, for the quarter, after a loss of $3.6 billion, or $9.53 a share, in the year-earlier period. Revenue rose to ...

The biotech company, which makes the Spikevax RNA-based Covid-19 vaccine, reported net income of $13 million, or 3 cents a share, compared with a loss of $3.6 billion, or $9.53 a share, in the same ...